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Figure S1 PCR genotyping of Slurp1 and Egfr alleles. We amplified a 377-bp Slurp1 fragment and a 230-bp Egfr fragment from genomic DnA isolated from mouse tail biopsies. To identify mutant alleles, the two differet PCR products were digested with AflII (Slurp1) or FokI (Egfr) and analyzed by agarose gel electrophoresis 
M E T H O D S L E T T E R T O T H E E D I T O R
An efficient method for gene knock-down by RNA interference in human skin mast cells
Abstract
Mast cells (MCs) from human skin have been notoriously resistant to gene manipulation, and a method to knock-down gene expression in in situ differentiated MCs is highly desired. The Dharmacon Accell ® transfection system proved successful on several "difficult-totransfect" cells. In the present work, we therefore tested this method on skin-derived MCs using different siRnA entities. The siRnA was readily taken up, followed by pronounced, specific reduction of gene and protein expression. Hence, we present the first efficient technique for the manipulation of gene expression in primary skin MCs ex vivo, which combines high transfection rates with retained cell viability.
| BACKGROUND
RnA interference (RnAi) has been firmly established to aid in the dissection of gene function. However, utility of this type of targeted knock-down critically depends on an efficient and nontoxic delivery method of the siRnA into the target cell, and this may be difficult to achieve with primary cells. The Accell ® system (Dharmacon Accell ® siRnA; GE Healthcare Dharmacon, CO, USA) uses chemically modified naked siRnAs for "self-delivery", that is without necessity of a transfection reagent (http://dharmacon.gelifesciences.com/rnai-and-custom-rna-synthesis/sirna/ Accell-sirna/).
Mast cells (MCs) are haematopoietic cells that complete differentiation exclusively in tissues like the skin, [1] [2] [3] and participate in various skin disorders and mediate pruritus symptoms. [4] [5] [6] [7] [8] [9] [10] Investigation of genes implicated in maturation, maintenance and function of primary tissue MCs has been hampered owing to the lack of techniques for ex vivo manipulation. While RnAi-mediated approaches have successfully been employed in MC lines and cultured MCs (the latter commonly generated in vitro from CD34 + progenitors), [11] [12] [13] [14] [15] [16] [17] [18] [19] of a quantitatively limited cell subset. To the best of our knowledge, an efficient method to reproducibly knock-down genes in primary skin
MCs, that were not cultured beforehand, has not been established yet.
| QUESTIONS ADDRESSED
We investigated whether primary human skin MCs would be amenable to RnAi ex vivo using the Accell ® system of self-delivery.
| EXPERIMENTAL DESIGN
Mast cells were isolated from either foreskin or breast skin tissue, yielding >98% pure MC suspensions. [20] [21] [22] [23] [24] [25] [26] [27] The study was approved by the university ethics committee, and experiments were conducted according to the Declaration of Helsinki Principles. Cells were subjected to gene knock-down according to the protocol provided by the manufacturer. In brief, 1×10 6 MCs were treated with 1 μM siRnA in 1 mL Accell ® siRnA Delivery Media (GE Healthcare Dharmacon) for the indicated times.
Fluorescence microscopy served to detect cellular uptake of labelled siRnA. RT-qPCR and immunoblots were performed to determine knock-down efficiency at the mRnA and protein level respectively. Annexin/PI staining and nuclear PI staining (for visualization of sub-G1 degraded DnA) served to assess cell viability. All methods are detailed in the Appendix S1.
| RESULTS

| Accell
® -supported RNA interference of skin MCs is highly efficient
We studied the efficiency of gene silencing in skin-derived MCs after isolation (MCs depicted in Figure 1A ) using reagents provided in the Accell ® siRnA optimization kit. In the first part, siRnA uptake was monitored using fluorescence microscopy of a PE-labelled siRnA (Accell ® Human Control siRnA Kit-Red). siRnA uptake was efficient, as there were basically no cells displaying no fluorescence ( Figure 1B) . With this result, we started to verify that uptake was actually followed by reduced expression of the respective target gene, for which the siRnAs were designed. Figure 1C+E demonstrates that RnAi was highly efficient with both siRnAs provided in the kit, one targeting glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the other Cyclophilin B (CyclB). In fact, GAPDH mRnA decreased to a mean of 18.3% of control, while CyclB transcript was reduced to 25.5%. Conversely, CyclB-specific siRnA had no impact on GAPDH mRnA expression and vice versa (not depicted), implying specificity.
There were no differences between foreskin-derived and breast skinderived MCs, and the data for both subsets were therefore combined in Figure 1C+E . Using antibodies to GAPDH and CyclB, we confirmed that RnAi-mediated mRnA reduction resulted in decreased expression of the protein products. Densitometry revealed a reduction down to 37.5% for GAPDH/β-actin and 25.9% for CyclB/β-actin vs control ( Figure 1D+F ). To determine knock-down duration, we finally analysed gene expression at different times after transfection. Knock-down efficiency was highest at day 2, still pronounced at day 4, and even still visible at day 6, indicating a fairly lasting effect (Fig. S1 ).
| Viability of skin-derived MCs after siRNA transfection
Transfection is a harsh process, which can result in substantial cell death.
To analyse whether transfection with siRnA affected MC survival, Nontarget
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we quantified survival of transfected (non-targeting siRnA) vs nontransfected cells, the latter cultured under identical conditions. Using the Annexin V-FITC-/propidium iodide (PI) method, [27] we found excellent survival rates, with 70%-80% of cells being double-negative after 48 hours (Figure 2A,B) . Importantly, this rate did not significantly differ between transfected and non-transfected cells. Viability was confirmed by the determination of sub-G1 cells, the fraction of which was below 12% in both groups ( Figure 2C ). This survival rate is remarkable given that the system employed is completely devoid of serum and growth factors.
| CONCLUSIONS
We present an efficient technique for the manipulation of gene expression in human skin MCs ex vivo. The Accell ® system yields high transfection rates, combined with retained cell viability. If prolonged culture is required or if apoptotic cells interfere with the downstream assay in question, Annexin V-binding cells can be efficiently removed with the cell death removal kit (data not illustrated). We conclude that Accell ® delivery is highly suitable for primary skinderived MCs, in accordance with reports on other hard-to-transfect cell types like (other) suspension cells and neurons. [28, 29] 
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Transforming growth factor β-inhibitor Repsox downregulates collagen expression of scleroderma dermal fibroblasts and prevents bleomycin-induced mice skin fibrosis 
